Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Total 13F shares
-
39,286,066
-
Share change
-
-237,618
-
Total reported value
-
$4,396,724,009
-
Put/Call ratio
-
173%
-
Price per share
-
$111.93
-
Number of holders
-
458
-
Value change
-
-$50,803,666
-
Number of buys
-
237
-
Number of sells
-
189
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q3 2021
As of 30 Sep 2021,
CRISPR Therapeutics AG - Common Stock (CRSP) was held by
458 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
39,286,066 shares.
The largest 10 holders included
ARK Investment Management LLC, Capital International Investors, Nikko Asset Management Americas, Inc., NEA Management Company, LLC, PRICE T ROWE ASSOCIATES INC /MD/, MACQUARIE GROUP LTD, Bellevue Group AG, LOOMIS SAYLES & CO L P, CREDIT SUISSE AG/, and BANK OF AMERICA CORP /DE/.
This page lists
461
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.